Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures
Melanie Schoof,Shweta Godbole,Thomas K Albert,Matthias Dottermusch,Carolin Walter,Annika Ballast,Nan Qin,Marlena Baca Olivera,Carolin Göbel,Sina Neyazi,Dörthe Holdhof,Catena Kresbach,Levke-Sophie Peter,Gefion Dorothea Epplen,Vanessa Thaden,Michael Spohn,Mirjam Blattner-Johnson,Franziska Modemann,Martin Mynarek,Stefan Rutkowski,Martin Sill,Julian Varghese,Ann-Kristin Afflerbach,Alicia Eckhardt,Daniel Münter,Archana Verma,Nina Struve,David T W Jones,Marc Remke,Julia E Neumann,Kornelius Kerl,Ulrich Schüller
DOI: https://doi.org/10.1038/s41467-023-43564-w
2023-11-24
Abstract:Pediatric high-grade gliomas of the subclass MYCN (HGG-MYCN) are highly aggressive tumors frequently carrying MYCN amplifications, TP53 mutations, or both alterations. Due to their rarity, such tumors have only recently been identified as a distinct entity, and biological as well as clinical characteristics have not been addressed specifically. To gain insights into tumorigenesis and molecular profiles of these tumors, and to ultimately suggest alternative treatment options, we generated a genetically engineered mouse model by breeding hGFAP-cre::Trp53Fl/Fl::lsl-MYCN mice. All mice developed aggressive forebrain tumors early in their lifetime that mimic human HGG-MYCN regarding histology, DNA methylation, and gene expression. Single-cell RNA sequencing revealed a high intratumoral heterogeneity with neuronal and oligodendroglial lineage signatures. High-throughput drug screening using both mouse and human tumor cells finally indicated high efficacy of Doxorubicin, Irinotecan, and Etoposide as possible therapy options that children with HGG-MYCN might benefit from.